Evidence map›Paper›PMID 38004490›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Design, Synthesis, Evaluation and Molecular Dynamics Simulation of Dengue Virus NS5-RdRp Inhibitors.

Keli Zong, Wei Li, Yijie Xu, Xu Zhao, Ruiyuan Cao, Hong Yan, Xingzhou Li

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Keli ZongFaculty of Environment and Life, Beijing University of Technology, 100 Pingleyuan, Beijing 100124, China.
Wei LiBeijing Institute of Pharmacology and Toxicology, 27 Taiping Road, Beijing 100850, China.
Yijie XuBeijing Institute of Pharmacology and Toxicology, 27 Taiping Road, Beijing 100850, China.
Xu ZhaoDepartment of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, 100 West Fourth Ring Road, Beijing 100071, China.
Ruiyuan CaoBeijing Institute of Pharmacology and Toxicology, 27 Taiping Road, Beijing 100850, China.
Hong YanFaculty of Environment and Life, Beijing University of Technology, 100 Pingleyuan, Beijing 100124, China.
Xingzhou LiBeijing Institute of Pharmacology and Toxicology, 27 Taiping Road, Beijing 100850, China.
Beijing University of Technology · CNChinese PLA General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dengue virus (DENV) is a major mosquito-borne human pathogen in tropical countries; however, there are currently no targeted antiviral treatments for DENV infection. Compounds

Indexed as

antiviral compoundsdengue virusmolecular dockingNS5-RdRp inhibitors

Identifiers

PMID38004490
PMCPMC10674617
OpenAlexW4388752098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.